1171 / 1578
/
Potential biological consequences of
SBRT dose distributions
Anti-vascular
effect
Endothelial
damage
Immune
effect
Low dose
bath
High doses
Small volumes
Low doses
Large volumes
Ø
Potential of altered toxicity profile in SRT
07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
39
/
Systematic review: SRT & targeted drugs
•
Very little data available considering large number of drugs,
cancer types and treatment sites
(Kroeze
Cancer Treat Rev. 2017)
Patients
Cranial
Extracranial
Antibodies
anti-EGFR / VEGF / HER2
Bevacizumab
215
201
14
Trastuzumab
7
7
0
Cetuximab
244
0
244
anti-CTLA-4
Ipilimumab
121
119
46
anti-PD-1
Nivolumab
27
27
0
Small molecules
EGFRi
Sorafenib
61
45
61
Sunitinib
76
75
62
Gefitinib/Erlotinib
71
43
48
ALKi
Crizotinib
39
15
39
BRAFi
129
128
20
MEKi
Trametinib
4
4
0
Total
994
664
534
07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
40